AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26557787
Drug: Stimulus control
RxNorm normalized name: Limulus polyphemus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulus control therapy
Trial: 26557787
Drug: Random assignment
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random assignment to treatments
Trial: 26557787
Drug: Preference allocation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference allocation to chosen treatment
Trial: 26559139
Drug: Interferon β-1a
RxNorm normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon β-1a 44 μg subcutaneously three times a week (SC tiw)
Trial: 26559790
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with escitalopram (mean daily dose 18.62 mg, SD 5.15) and memantine (mean daily dose 13.62 mg, SD 6.67)
Trial: 26559790
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with escitalopram and memantine
Trial: 26559790
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with escitalopram and memantine in the amnestic mild cognitive impairment subsample (n = 22)
Trial: 26560486
Drug: Nintedanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib plus pemetrexed (500 mg/m2 iv on Day 1, nintedanib 100 mg bid escalating to 200 mg bid on days 2-21)
Trial: 26561629
Drug: ¹³C-lycopene (10.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ¹³C-lycopene (10.2 mg)
Trial: 26561916
Drug: Bovine activated
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine activated factors IIa/VIIa/IXa/Xa (SeraSeal) applied topically via catheters as initial hemostasis in group A (5 mL)
Trial: 26561916
Drug: Bovine activated
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine activated factors IIa/VIIa/IXa/Xa (SeraSeal) applied topically via catheters as rescue therapy in group B (5 mL)
Trial: 26562532
Drug: Broad-spectrum antibiotics
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum antibiotics (vancomycin 500 mg, gentamycin 40 mg, meropenem 500 mg once-daily for 4 days)
Trial: 26562532
Drug: Broad-spectrum antibiotics
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum antibiotics (vancomycin, gentamycin, meropenem)
Trial: 26562836
Drug: Synthetic ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic ACTH (intramuscular injections, max 1 mg twice a week for 9 months)
Trial: 26562836
Drug: Cyclophosphamide and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide and steroids (historical control)
Trial: 26563229
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for generalized anxiety disorder, panic disorder, social anxiety disorder (SAD), or post-traumatic stress disorder
Trial: 26563229
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for social anxiety disorder (SAD)
Trial: 26563323
Drug: Latanoprostene bunod
RxNorm normalized name: Latanoprostene bunod
DrugBank: Latanoprostene bunod (DB11660)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Latanoprostene bunod 0.024% instilled once daily (QD) for 14 days
Trial: 26565008
Drug: RBX2660 (microbiota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBX2660 (microbiota suspension) administered via enema
Trial: 26566161
Drug: Etravirine 5.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 5.2 mg/kg twice daily with a background regimen (boosted protease inhibitor plus nucleoside/nucleotide reverse transcriptase inhibitors, optional enfuvirtide/raltegravir)
Trial: 26566161
Drug: Etravirine 5.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 5.2 mg/kg twice daily
Trial: 26566446
Drug: Bollywood dance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bollywood dance classes (1 hour, twice per week for 8 weeks)
Trial: 26566914
Drug: Genetic testing
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic testing for the m.3243A>G MELAS mutation
Trial: 26567113
Drug: [(64)Cu]DOTA-patritumab (9.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(64)Cu]DOTA-patritumab (9.0 mg/kg)
Trial: 26567860
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose infusion (IVGI)
Trial: 26568466
Drug: 3-day treatment
RxNorm normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day treatment (15 mg/m² every 8 hours for three consecutive days/cycle/6 weeks)
Trial: 26568466
Drug: 5-day treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day treatment (20 mg/m² once daily on days 1-5/cycle/4 weeks)
Trial: 26568466
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (3-day and 5-day)
Trial: 26571268
Drug: Bee venom
RxNorm normalized name: Bee venom
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bee venom treatment (subchronic)
Trial: 26571268
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of bee venom
Trial: 26571268
Drug: Apamin (blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apamin (blocker of SK channels)
Trial: 26571268
Drug: CyPPA (positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyPPA (positive modulator of SK channels)
Trial: 26571268
Drug: Control (neuroleptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (neuroleptic treatment and 6-hydroxydopamine injection)
Trial: 26571311
Drug: rSm14/GLA-SE vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rSm14/GLA-SE vaccine (50 μg rSm14 with 10 μg GLA-SE, intramuscularly, three doses with 30-day intervals)
Trial: 26573078
Drug: DPYD*2A genotype-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPYD*2A genotype-guided dosing (initial dose reduction of ≥ 50%)
Trial: 26573078
Drug: DPYD*2A genotype-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPYD*2A genotype-guided dosing
Trial: 26573686
Drug: Other analgesic
RxNorm normalized name: OTHER ANALGESICS AND ANTIPYRETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other analgesic drugs
Trial: 26574583
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (300 µg PM(2.5)/m(3))
Trial: 26575422
Drug: Intra-tumor injection
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-tumor injection of AvidinOX with low dose bCet
Trial: 26576059
Drug: Hydroxyurea (15-35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (15-35 mg/kg/day)
Trial: 26577301
Drug: PI combined
RxNorm normalized name: PI-103
DrugBank: PI-103 (DB17046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI combined with external beam radiation therapy (PI + EBRT)
Trial: 26578722
Drug: Everolimus (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (30 mg weekly) with Carboplatin (area under the curve 6) and Paclitaxel (200 mg/m²) every 3 weeks
Trial: 26578731
Drug: Hepatic artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic artery infusion (HAI) with triplet chemotherapy (irinotecan 180 mg/m², oxaliplatin 85 mg/m², 5-fluorouracil 2800 mg/m²) and systemic cetuximab (500 mg/m²) every 14 days.
Trial: 26578731
Drug: Hepatic artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic artery infusion (HAI) with triplet chemotherapy and systemic cetuximab.
Trial: 26581135
Drug: 60 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 Gy intensity modulated radiation therapy with concurrent weekly intravenous cisplatinum (30 mg/m(2))
Trial: 26581137
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) with a prescribed dose of 48 Gy at the isocenter in 4 fractions
Trial: 26582805
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) insulin therapy
Trial: 26582853
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% ACB with 20 ml
Trial: 26582853
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% ACB with varying volumes (5 ml, 10 ml, 15 ml, 20 ml)
Trial: 26583301
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of relaxin over 48 hours
Trial: 26584601
Drug: Endoscopic remission
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic remission defined as absence of white exudates, moderate or severe rings, strictures, or combination of furrows and edema
Trial: 26585432
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for 21 days
Trial: 26588924
Drug: ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibrutinib 420 mg
Trial: 26588924
Drug: ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibrutinib 560 mg
Trial: 26588924
Drug: ibrutinib 140
RxNorm normalized name: ibrutinib 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibrutinib 140 mg and 280 mg (single-dose phase)
Trial: 26588924
Drug: ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibrutinib 420 mg (multiple-dose phase)
Trial: 26589752
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of allogeneic mesenchymal stromal cells (MSCs) at a median dose of 2.7 × 10(6) cells/kg/infusion, range 1.3-4.5, given weekly for 2 to 5 weeks, in addition to standard rabbit ATG and cyclosporine.
Trial: 26589963
Drug: Canakinumab treatment
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab treatment in SJIA patients
Trial: 26589963
Drug: Active AOSD
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active AOSD prior to canakinumab treatment
Trial: 26590174
Drug: Intravenous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous abatacept (∼10 mg/kg) plus MTX for 24 weeks
Trial: 26595450
Drug: 3-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-drug regimen (ledipasvir, sofosbuvir, GS-9451) for 4 weeks
Trial: 26595450
Drug: 4-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-drug regimen (ledipasvir, sofosbuvir, GS-9451, GS-9669) for 4 weeks
Trial: 26597180
Drug: Dasotraline 4
RxNorm normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasotraline 4 or 8 mg/day
Trial: 26597180
Drug: Dasotraline (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasotraline (various doses from 0.2 to 36 mg)
Trial: 26597443
Drug: Cetuximab in
RxNorm normalized name: cetuximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab in combination with 5-fluorouracil (5FU) and mitomycin C (MMC) during chemoradiotherapy (CRT)
Trial: 26597443
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5FU) 800 mg/m(2) on RT days 1-4 and 29-32 and mitomycin C (MMC) 8 mg/m(2) on days 1 and 29
Trial: 26597443
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of cetuximab
Trial: 26597653
Drug: Topical mosquito
RxNorm normalized name: mosquito allergenic extract
DrugBank: Aedes taeniorhynchus (DB10691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mosquito repellent distribution scheme (2-weekly bottle exchange programme)
Trial: 26597937
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment provided by family physician.
Trial: 26598545
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HER2-PET/CT and FDG-PET/CT
Trial: 26602014
Drug: Toremifene 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 180 mg daily
Trial: 26602164
Drug: Plerixafor (CXCR4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (CXCR4 antagonist)
Trial: 26603536
Drug: lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lanreotide Autogel 120 mg every 4 weeks
Trial: 26603828
Drug: Duloxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30 mg/day for 7 days, then 60 mg/day for 4 weeks)
Trial: 26606867
Drug: self-complementary AAV
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2 at low dose (5 × 10(9) vg)
Trial: 26606867
Drug: self-complementary AAV
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2 at medium dose (2.46 × 10(10) vg)
Trial: 26607424
Drug: EMA-approved dose
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMA-approved dose
Trial: 26607424
Drug: FDA-approved dose
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA-approved dose
Trial: 26607977
Drug: Compliance with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliance with dose constraints for target volumes
Trial: 26607977
Drug: Compliance with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliance with dose constraints for OAR
Trial: 26608460
Drug: Lateral flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral flow test (LFT) with G12 monoclonal antibody for gluten immunogenic peptides (GIP)
Trial: 26608976
Drug: OROS-MPH (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS-MPH (18 mg, 36 mg, or 54 mg)
Trial: 26610172
Drug: Group drumming
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group drumming intervention, details on dosage and duration not available
Trial: 26612014
Drug: ledipasvir/sofosbuvir (LDV/SOF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ledipasvir/sofosbuvir (LDV/SOF) (90 mg/400 mg) daily for 12 weeks
Trial: 26612014
Drug: ledipasvir/sofosbuvir (LDV/SOF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ledipasvir/sofosbuvir (LDV/SOF) + GS-9451 (80 mg/day) daily for 6 weeks
Trial: 26612014
Drug: ledipasvir/sofosbuvir (LDV/SOF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ledipasvir/sofosbuvir (LDV/SOF) + GS-9669 (500 mg twice daily) for 6 weeks
Trial: 26612014
Drug: Recent drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recent drug use
Trial: 26612321
Drug: Neoadjuvant concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant concurrent chemoradiotherapy with hematopoietical bone marrow sparing
Trial: 26612701
Drug: PPI (Proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI (Proton Pump Inhibitors)
Trial: 26612701
Drug: H2 RA
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: H2 RA (H2-receptor antagonists)
Trial: 26612870
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg posaconazole (as tablets) once daily (twice daily on day 1) for up to 28 days
Trial: 26612873
Drug: Intravesicular cidofovir
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesicular cidofovir (2.5-5 mg/kg in 50-100 mL of normal saline) administered via transurethral catheter after oral probenecid (2 g) for up to 2 h of dwell time.
Trial: 26612979
Drug: Dabigatran 220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 220 mg once daily after switching from enoxaparin 40 mg for thromboprophylaxis
Trial: 26612979
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg for thromboprophylaxis
Trial: 26614268
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg once daily for 4 weeks
Trial: 26614966
Drug: Disulfiram 500
RxNorm normalized name: disulfiram 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram 500 mg
Trial: 26614966
Drug: Disulfiram 1000
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram 1000 mg
Trial: 26614966
Drug: Disulfiram 2000
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram 2000 mg
Trial: 26615061
Drug: Hydroxyurea treatment
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea treatment with a pharmacokinetic-guided dosing strategy, initial dose of 20 mg/kg oral dose.
Trial: 26615061
Drug: Pharmacokinetic-guided dosing
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic-guided dosing strategy
Trial: 26616030
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy (GDMT) plus revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery)
Trial: 26618098
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma therapy (2 units)
Trial: 26619773
Drug: Clozapine treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine treatment, dosage and duration not specified
Trial: 26619834
Drug: Vorinostat 400
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat 400 mg plus bortezomib 1.3 mg/m(2)
Trial: 26621580
Drug: Quercetin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (up to 5 g daily)
Trial: 26622643
Drug: Belinostat in
RxNorm normalized name: belinostat Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide
Trial: 26625449
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (both doses)
Trial: 26627079
Drug: Volasertib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib (300 mg)
Trial: 26627079
Drug: Volasertib (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib (350 mg)
Trial: 26627079
Drug: Volasertib (200-350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib (200-350 mg)
Trial: 26627107
Drug: E/C/F/TAF (elvitegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E/C/F/TAF (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, TAF 10 mg)
Trial: 26628614
Drug: ACP-501 (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACP-501 (recombinant human LCAT) at 0.9 mg/kg
Trial: 26628614
Drug: ACP-501 (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACP-501 (recombinant human LCAT) at 3.0 mg/kg
Trial: 26628614
Drug: ACP-501 (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACP-501 (recombinant human LCAT) at 9.0 mg/kg
Trial: 26628614
Drug: ACP-501 (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACP-501 (recombinant human LCAT) at 13.5 mg/kg
Trial: 26628838
Drug: EVL plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVL plus somatostatin (250 mcg/hr)
Trial: 26630396
Drug: Pulmonary vasodilator
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary vasodilator therapy (phosphodiesterase-5 inhibitors, 88% at entry, 87% after 1 year)
Trial: 26630396
Drug: Pulmonary vasodilator
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary vasodilator therapy (phosphodiesterase-5 inhibitors)
Trial: 26631428
Drug: Lurasidone 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 20, 40, 80, 120, and 160 mg/d
Trial: 26631428
Drug: Lurasidone doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone doses <120 mg/d
Trial: 26631428
Drug: Lurasidone (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (multiple doses)